Biocon Limited

BIOCON

INE376G01013

Biotechnology & Medical Research

Market Closed - NSE India S.E. Other stock markets 07:43:47 2024-04-26 am EDT			5-day change	1st Jan Change
306.4 ^INR	+5.06%		+17.10%	+22.73%

Apr. 18	India's Biocon developing its own version of Wegovy, clinical trial likely next year	RE
Apr. 18	Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	MT

Biocon Limited Appoints Peter Piot as an Independent Director

January 21, 2021 at 02:59 am EST

Biocon Limited announced that Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director.

Latest news about Biocon Limited

India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	Apr. 17	MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	Apr. 17	CI
Biocon Board to Consider Dividend for Fiscal 2024	Apr. 10	MT
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	Apr. 02	MT
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	Mar. 31	CI
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	Mar. 27	CI
Biocon Limited Receives an Order from the Reserve Bank of India	Mar. 22	CI
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	Mar. 15	MT
Biocon's CFO Resigns	Mar. 14	MT
Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer	Mar. 14	CI
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	Mar. 14	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	Mar. 14	RE
Biocon Limited Announces Executive Appointments	Mar. 04	CI
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada	Mar. 04	MT
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	Feb. 27	RE
INDIA STOCKS-Indian shares muted after five-session rally, tracking Asian peers	Feb. 19	RE
Jefferies Adjusts Biocon’s Price Target to INR250 From INR255, Keeps at Hold	Feb. 12	MT
Biocon Swings to Profit in Fiscal Q3	Feb. 09	MT
Transcript : Biocon Limited, Q3 2024 Earnings Call, Feb 09, 2024	Feb. 08
Indian shares set for a muted start, tracking Asian peers	Feb. 08	RE
Biocon CFO Resigns	Feb. 08	MT
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	Feb. 08	RE
Biocon Limited Announces Indranil Sen Resigns as Chief Financial Officer, Effective March 15, 2024	Feb. 08	CI
Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024	Feb. 08	CI

Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q4 2024 Earnings Release

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Biocon Limited

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

306.4 INR

Average target price

279.1 INR

Spread / Average Target

-8.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOCON LIMITED	+22.73%	4.18B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs

Biocon Limited

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Biocon Limited Appoints Peter Piot as an Independent Director

Latest news about Biocon Limited

Chart Biocon Limited

Company Profile

Income Statement Evolution

Ratings for Biocon Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs